News
China’s 3SBio Soars on Granting Pfizer New Cancer Drug Rights in USD6 Billion Deal
3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a bispecific antibody targeting PD-1 and VEGF for cancer treatment, according to the agreement announced yesterday. The deal also includes an option for Pfizer to acquire commercialization rights in China.
The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...
Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...
No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 ...
The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...
Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics ... If those results are positive the partners have said they could file for approval in the ...
Under the multi-year collaboration agreement, Guardant and Pfizer ... for its global clinical trials, which include China cohorts. In July 2022, Guardant announced a strategic partnership with ...
With the company’s Q1 2025 results on Tuesday, Pfizer (NYSE:PFE) indicated plans to explore acquisitions or partnerships to add cardiometabolic assets, including weight loss therapies ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback